This is an archive of past discussions. Do not edit the contents of this page. If you wish to start a new discussion or revive an old one, please do so on the current talk page. |
Archive 1 | Archive 2 |
Seppi333,
May I use your material ( /info/en/?search=Template:Psychostimulant_addiction) in a presentation to a college of pharmacy? If so how would you like for me to attribute credit to you? I'll be making alterations to focus the material on my presentation topic.
(I'm a wikipedia newb...)
Cicatrix768 Cicatrix768 ( talk) 16:05, 3 November 2016 (UTC)
@ Boghog: You gave me a lot of feedback when I was creating this diagram, so I was wondering what you thought about this. How do you feel about this proposed revision? Seppi333 ( Insert 2¢) 05:25, 6 November 2016 (UTC)
References for this section
|
---|
|
Has anyone proposed a multiple column TOC option? You know how damn much white space growing TOCs create; the horizontal layout can fix this dead space but is terrible to use. (I believe that you've been positioning the addiction glossary to compensate, in part.) What are your thoughts on multi-column TOCs? — βox73 (৳alk) 13:26, 25 January 2017 (UTC)
{{
TOC limit}}
or merge subsections within an article into their parent headings.
Seppi333 (
Insert 2¢) 21:49, 25 January 2017 (UTC){{
Addiction glossary}}
is based upon {{
Transcription factor glossary}}
and similar glossaries, so I'll need to change the header color in several templates when I implement it.{{
Addiction glossary}}
has a |class=
parameter for setting the table class; in the amphetamine article, this parameter is set to "wikitable mw-collapsible mw-collapsed". The default class parameter for the addiction glossary is "toccolours", which is not a wikitable class. When using the "toccolours" class parameter, the rows within a table are not partitioned by table cells like they are when using a wikitable class.{{
Addiction glossary}}
and {{
Transcription factor glossary}}
?
Seppi333 (
Insert 2¢) 19:24, 28 January 2017 (UTC)
Are you still blocked? According to Special:BlockList, you are not. Let me know. I am watching this page. - Ad Orientem ( talk) 04:07, 26 February 2017 (UTC)
Check your email. - Ad Orientem ( talk) 00:07, 27 February 2017 (UTC)
Hello:
I am an undergraduate student at LSE. Psychology is my optional course. Enriching a psychological entry on Wikipedia is one of our assessment. Reward system is the entry allocated to me. We have to write 750-1000 words in addition to the original piece. I am totally a new hand to Wikipedia. If I do something not very good, please feel free to give me your advice! Thank you! — Preceding unsigned comment added by XUY49 ( talk • contribs) 00:25, 14 March 2017 (UTC)
Two years! |
---|
-- Gerda Arendt ( talk) 07:12, 3 April 2017 (UTC)
Please check out my comment.-- Penbat ( talk) 10:19, 9 April 2017 (UTC)
You're a fine editor but I take issue with the abrasive tone of your edit summaries regardless of their validity. But this went further. I don't want interact with you. I can't, at least presently. — βox73 (৳alk) 01:57, 20 April 2017 (UTC)
Seppi, would you like me to post this GA nom,beta-Hydroxy beta-methylbutyric acid to do Wikipedia_talk:WikiProject_Medicine so you can get the ball rolling, let me know(I'm sure it'll pass easily)-- Ozzie10aaaa ( talk) 10:37, 20 April 2017 (UTC)
Please can you do a one or two paragraph subsection on Addiction here Reinforcement#Applications thanks. I've done a placeholder inspired by you last edit :-) Reinforcement#Addiction -- Penbat ( talk) 22:04, 17 May 2017 (UTC)
Reflist
|
---|
References
|
It is definately good enough for now. Thanks. Hopefuly you will get time to develop it further at some point.-- Penbat ( talk) 08:55, 18 May 2017 (UTC)
Hi. We're into the last five days of the Women in Red World Contest. There's a new bonus prize of $200 worth of books of your choice to win for creating the most new women biographies between 0:00 on the 26th and 23:59 on 30th November. If you've been contributing to the contest, thank you for your support, we've produced over 2000 articles. If you haven't contributed yet, we would appreciate you taking the time to add entries to our articles achievements list by the end of the month. Thank you, and if participating, good luck with the finale! — Preceding unsigned comment added by MediaWiki message delivery ( talk • contribs) 03:11, 26 November 2017 (UTC)
Thanks for the thanks Seppi -- Iztwoz ( talk) 23:18, 24 March 2017 (UTC)
Thanks for having a look at the article and making some changes, Seppi333. We're aiming to nominate for GA at some point in the medium term.
It's been quite hard given the extensive role of the human brain to balance accuracy, prose length, comprehensiveness and readability. If you haven't had a look through the whole article I'd be quite grateful if you could skim along to make sure there's nothing unusual about it, given you're one of the few editors around who may have an informed view about it. There's a couple of editors (including one now blocked from editing it) so we can't speak to all the edits, and I plan on editing to finish up the modern history and clinical significance sections tonight... but for an article like this, more eyes will be better
Hope that you're well, -- Tom (LT) ( talk) 21:01, 25 March 2017 (UTC)
The 2016 Cure Award | |
In 2016 you were one of the top ~200 medical editors across any language of Wikipedia. Thank you from Wiki Project Med Foundation for helping bring free, complete, accurate, up-to-date health information to the public. We really appreciate you and the vital work you do! Wiki Project Med Foundation is a user group whose mission is to improve our health content. Consider joining here, there are no associated costs. |
Thanks again :-) -- Doc James along with the rest of the team at Wiki Project Med Foundation 18:08, 3 May 2017 (UTC)
Your account has been granted the "templateeditor" user permission, allowing you to edit templates and modules that have been protected with template protection. It also allows you to bypass the title blacklist, giving you the ability to create and edit editnotices. Before you use this user right, please read Wikipedia:Template editor and make sure you understand its contents. In particular, you should read the section on wise template editing and the criteria for revocation.
You can use this user right to perform maintenance, answer edit requests, and make any other simple and generally uncontroversial edits to templates, modules, and edinotices. You can also use it to enact more complex or controversial edits, after those edits are first made to a test sandbox, and their technical reliability as well as their consensus among other informed editors has been established. If you are willing to process edit requests on templates and modules, keep in mind that you are taking responsibility to ensure the edits have consensus and are technically sound.
This user right gives you access to some of Wikipedia's most important templates and modules; it is critical that you edit them wisely and that you only make edits that are backed up by consensus. It is also very important that no one else be allowed to access your account, so you should consider taking a few moments to secure your password.
If you do not want this user right, you may ask any administrator to remove it for you at any time.
Happy template editing! Alex Shih Talk 12:10, 10 July 2017 (UTC)
On 12 July 2017, Did you know was updated with a fact from the article Pavlovian-instrumental transfer, which you recently created, substantially expanded, or brought to good article status. The fact was ... that a classically conditioned stimulus can affect operant behavior and motivation through Pavlovian-instrumental transfer? The nomination discussion and review may be seen at Template:Did you know nominations/Pavlovian-instrumental transfer. You are welcome to check how many page hits the article got while on the front page ( here's how, Pavlovian-instrumental transfer), and it may be added to the statistics page if the total is over 5,000. Finally, if you know of an interesting fact from another recently created article, then please feel free to suggest it on the Did you know talk page.
Alex Shih Talk 00:02, 12 July 2017 (UTC)
Thanks for your help! :3 2601:19A:4003:50:708B:26A:171F:F407 ( talk) 03:42, 14 July 2017 (UTC)
Hello. Your account has been granted the "pending changes reviewer" userright, allowing you to review other users' edits on pages protected by pending changes. The list of articles awaiting review is located at Special:PendingChanges, while the list of articles that have pending changes protection turned on is located at Special:StablePages.
Being granted reviewer rights neither grants you status nor changes how you can edit articles. If you do not want this user right, you may ask any administrator to remove it for you at any time.
See also:
Malinaccier ( talk) 16:26, 31 July 2017 (UTC)
I was wondering what you think about elaborating more about the effects of DA signalling on downstream targets such as the beta subunits of GABA, trafficking of GluA1/GluN2B, and mTOR signalling. I dont see much of that in the dopamine or dopamine receptor articles, and was wondering if you had any thoughts about where these additions would go if they were significant enough. Im considering adding a lot of it to the nucleus accumbens article, since quite a lot of this research bas focused in signalling in NAcc MSNs. Petergstrom ( talk) 22:00, 30 August 2017 (UTC)
{{
psychostimulant addiction}}
is that it involved 2 signaling pathways that converge at We stick with secondary source generally. I am not supportive of filling articles full of case reports. IMO that is clutter. Doc James ( talk · contribs · email) 17:23, 28 September 2017 (UTC)
Hey,
I think it's time that we try to follow through on the page rename from Adderall to Mixed Amphetamine Salts that was recently discussed on Talk:Amphetamine (specifically at Talk:Amphetamine/Archive 7#Mydayis). Box73 agreed when you asked him about his opinion on it and the only glimmer of opposition was from an IP editor that did not seem to be acquainted with the topic and did not further participate in the discussion after their initial comment.
I have created a draft article in my userspace with my proposed edits to Adderall in it that would sufficiently expand the scope of the article to include the other two MAS products and take the focus away from Adderall specifically and change it to the broader scope of mixed amphetamine salts. It's accessible at User:Garzfoth/Draft:Mixed Amphetamine Salts. While some additional work needs to be done to more clearly explain the differences between equivalent mixtures of amphetamine bases and actual mixtures of amphetamine salts, my recent re-read of FDA application # 208147Orig1s000 for Dyanvel made it clear to me that it is indeed completely appropriate to categorize the salts and the equivalent mixtures of bases under the same article/name, and I made enough changes to hopefully communicate the basics without being misleading (difficult to do in this case).
I am a bit uncertain about how exactly the process to proceed would work. It seems that I would need to follow the process in Wikipedia:Requested_moves#Requesting_controversial_and_potentially_controversial_moves, but I wanted to run this by you before starting anything so I could get your feedback on the proposed edits in my draft first, and I'm not certain about some of the particularities of moving this page (the problem is mainly that I don't know if it'd be better to make the edits prepared on User:Garzfoth/Draft:Mixed Amphetamine Salts when I request the move, or if I should wait until the move is approved even though the edits and the move should really go hand-in-hand — but I am also not sure if I need to reiterate all of my arguments in a move request, or if I can just briefly summarize them and link to the past two places where I went into more detail - I don't want to end up with a 35,000–45,000 char request that has to be mostly collapsed, which is approximately what it'd end up being if I actually rehashed all of my arguments within the request in full detail and included all those refs I dug up, as well as the new ones I now have...any advice on that?). Garzfoth ( talk) 08:04, 14 October 2017 (UTC)
Thank you for the excellent work at Template talk:Tryptophan metabolism by human microbiota - you've convinced me of the value of annotated diagrams! Slashme ( talk) 21:58, 2 November 2017 (UTC) |
| wydte = 580
parameter to | wydte = 600
.{{
Annotated image 4}}
specify the width and height of the thumbnail for the image; the "image-width" parameter specifies the width of the image (the image's height is automatically scaled based upon that value and its aspect ratio). The reason there's two width parameters is to allow you to crop or expand the area around the top/bottom/left/right sides of any image; using the "image-top", "image-left", "image-width", "width", and "height" parameters together lets you crop/expand images like that.
Seppi333 (
Insert 2¢) 22:28, 2 November 2017 (UTC)
Please be aware that your signature uses deprecated <font>
tags, which are causing
Obsolete HTML tags lint errors. You are encouraged to change
[[User:Seppi333|'''<font color="#32CD32">Seppi</font>''<font color="Black">333</font>''''']] ([[User Talk:Seppi333|Insert '''2¢''']])
→
Seppi333 (
Insert 2¢)to
[[User:Seppi333|'''<span style="color: #32CD32;">Seppi</span>''<span style="color: Black;">333</span>''''']] ([[User Talk:Seppi333|Insert '''2¢''']])
→
Seppi333 (
Insert 2¢)That's my 2¢.— Anomalocaris ( talk) 06:44, 9 November 2017 (UTC)
That's my 2¢– LOL. Anyway, I've made the changes you've indicated. Thanks for letting me know. Seppi333 ( Insert 2¢) 06:50, 9 November 2017 (UTC)
Hello, Seppi333.
I noticed you've done some constructive editing recently. |
{{
NPR invite}}
template needs to be substituted (i.e., use {{subst:NPR invite}}
instead of {{NPR invite}}
); otherwise, it doesn't add your signature.
Seppi333 (
Insert 2¢) 07:08, 21 November 2017 (UTC)
Hello Seppi333. Your account has been added to the "New page reviewers
" user group, allowing you to review new pages and mark them as
patrolled, tag them for maintenance issues, or in some cases, tag them for deletion. The list of articles awaiting review is located at the
New Pages Feed. New page reviewing is a vital function for policing the quality of the encylopedia, if you have not already done so, you must read the new tutorial at
New Pages Review, the linked guides and essays, and fully understand the various
deletion criteria. If you need more help or wish to discuss the process, please join or start a thread at
page reviewer talk.
The reviewer right does not change your status or how you can edit articles. If you no longer want this user right, you may ask any administrator to remove it for you at any time. In case of abuse or persistent inaccuracy of reviewing, the right can be revoked at any time by an administrator. TonyBallioni ( talk) 15:10, 21 November 2017 (UTC)
Hello Seppi333,
Please could you explain why my edit was wrong/bad and why you reverted it in this edit? Thank you! -- Treetear ( talk) 22:59, 25 November 2017 (UTC)
Hi there, I'm pleased to inform you that I've begun reviewing the article Beta-Hydroxy beta-methylbutyric acid you nominated for GA-status according to the criteria. This process may take up to 7 days. Feel free to contact me with any questions or comments you might have during this period. Message delivered by Legobot, on behalf of Tom (LT) -- Tom (LT) ( talk) 06:01, 28 November 2017 (UTC)
The Wikimedia Foundation Community health initiative (led by the Safety and Support and Anti-Harassment Tools team) is conducting a survey for en.wikipedia contributors on their experience and satisfaction level with the Administrator’s Noticeboard/Incidents. This survey will be integral to gathering information about how this noticeboard works - which problems it deals with well, and which problems it struggles with.
The survey should take 10-20 minutes to answer, and your individual responses will not be made public. The survey is delivered through Google Forms. The privacy policy for the survey describes how and when Wikimedia collects, uses, and shares the information we receive from survey participants and can be found here:
If you would like to take this survey, please sign up on this page, and a link for the survey will be mailed to you via Special:Emailuser.
Please be aware this survey will close Friday, Dec. 8 at 23:00 UTC.
Thank you on behalf of the Support & Safety and Anti-Harassment Tools Teams, Patrick Earley (WMF) talk 21:14, 6 December 2017 (UTC)
Hi there! In your revert of my edit of Transactivation you commented that "Wikilinks should not be placed inside a reference quote". Could you please substantiate that? DadaNeem ( talk) 22:49, 11 December 2017 (UTC)
Hi. You recently changed the LRT page by switching the numerator and denominator in the definition of LR. As I understand it (I am not an expert) it occurs both ways in the literature, so either way is OK, but now there are inconsistencies, I believe, with other parts of the article. e.g.: in the 'Simple hypotheses' section: 'In the form stated here, the likelihood ratio is small if the alternative model is better than the null model.', and in the 'Interpretation' section: 'The likelihood ratio test rejects the null hypothesis if the value of this statistic is too small.', and 'The numerator corresponds to the likelihood of an observed outcome under the null hypothesis. The denominator ...'. And maybe there are other inconsistencies. I don't know whether is would be better to revert to null model likelihood in numerator, or fix the statements inconsistent with your version. Perhaps you could do one or the other. Thanks. tom fisher-york ( talk) 18:24, 22 December 2017 (UTC)
Looks like I was confused about who did the latest revision. I'll put this on the article's talk page as I should have. — Preceding unsigned comment added by Tomfy ( talk • contribs) 18:33, 22 December 2017 (UTC)
Hi Seppi333, I just wanted to let you know that I have added the "autopatrolled" permission to your account, as you have created numerous, valid articles. This feature will have no effect on your editing, and is simply intended to reduce the workload on new page patrollers. For more information on the autopatrolled right, see Wikipedia:Autopatrolled. Feel free to leave me a message if you have any questions. Happy editing! TonyBallioni ( talk) 05:46, 23 December 2017 (UTC)
Merry Christmas and a Prosperous 2018! | |
Hello Seppi333, may you be surrounded by peace, success and happiness on this
seasonal occasion. Spread the
WikiLove by wishing another user a
Merry Christmas and a
Happy New Year, whether it be someone you have had disagreements with in the past, a good friend, or just some random person. Sending you a heartfelt and warm greetings for Christmas and New Year 2018. Spread the love by adding {{ subst:Seasonal Greetings}} to other user talk pages. |
A blessed feast to you and yours. - Ad Orientem ( talk) 15:22, 25 December 2017 (UTC)
The article Beta-Hydroxy beta-methylbutyric acid you nominated as a good article has passed ; see Talk:Beta-Hydroxy beta-methylbutyric acid for comments about the article. Well done! If the article has not already been on the main page as an "In the news" or "Did you know" item, you can nominate it to appear in Did you know. Message delivered by Legobot, on behalf of Tom (LT) -- Tom (LT) ( talk) 22:41, 25 December 2017 (UTC)
Hi Seppi333, here is the hatnote from Template:Main section. Credit to Mclay1 who originally wrote this. {{Hatnote|The main section for this topic is on the page [[{{{1}}}]], in the section [[{{{1}}}#{{{2}}}|{{{2}}}]].}}
Actually I am his father, and I don't know the details of where the insignia were worn. Feel free to adjust
ed
Ecragg ( talk) 10:39, 9 February 2018 (UTC)
Hey Seppi333, I just wanted to notify you as to an edit on the nucleus accumbens page I just made. From what was already written in the function section, it seemed as if the page was suggesting that increased excitability in NAcc MSNs is responsible for reward, so I changed the wording a bit, along with adding reviews of how reduced excitability is the predominant response in the NAcc. Petergstrom ( talk) 17:57, 10 February 2018 (UTC)
can you help User talk:Doc James#apparently not?(update... whenever you have time, just realized you've been out for 2 weeks)-- Ozzie10aaaa ( talk) 21:32, 3 March 2018 (UTC)
Three years! |
---|
-- Gerda Arendt ( talk) 10:27, 3 April 2018 (UTC)
Thank you for Beta-Hydroxy beta-methylbutyric acid, "a natural product in humans which is used as a medical food ingredient and dietary supplement; it has medical and athletic performance-enhancing applications for preventing/reversing muscle wasting and improving body composition respectively"! - I'd have difficulties to even remember the name, and appreciate highly what you did to make us understand. -- Gerda Arendt ( talk) 06:30, 28 May 2018 (UTC)
I have created new content about chromium dietary supplements. Because I have a declared COI, I placed it as New section in Chromium deficiency Talk. I am asking you and several other editors with an interest in nutrition/supplements to look at it and comment, perhaps making changes and/or stating that it is appropriate to move into the article, or not. A separate question is whether it belongs in Chromium deficiency, Chromium, or both. Thank you for the consideration. David notMD ( talk) 11:49, 16 April 2018 (UTC)
Hello,
There will be some changes to the way wikitext is parsed during the next few weeks. It will affect all namespaces. You can see a list of pages that may display incorrectly at Special:LintErrors. Since most of the easy problems have already been solved at the English Wikipedia, I am specifically contacting tech-savvy editors such as yourself with this one-time message, in the hope that you will be able to investigate the remaining high-priority pages during the next month.
There are approximately 10,000 articles (and many more non-article pages) with high-priority errors. The most important ones are the articles with misnested tags and table problems. Some of these involve templates, such as infoboxes, or the way the template is used in the article. In some cases, the "error" is a minor, unimportant difference in the visual appearance. In other cases, the results are undesirable. You can see a before-and-after comparison of any article by adding ?action=parsermigration-edit to the end of a link, like this: /info/en/?search=Arthur_Foss?action=parsermigration-edit (which shows a difference in how {{ infobox ship}} is parsed).
If you are interested in helping with this project, please see Wikipedia:Linter. There are also some basic instructions (and links to even more information) at https://lists.wikimedia.org/pipermail/wikitech-ambassadors/2018-April/001836.html You can also leave a note at WT:Linter if you have questions.
Thank you for all the good things you do for the English Wikipedia. Whatamidoing (WMF) ( talk) 21:18, 19 April 2018 (UTC)
Hello Seppi333. You've been warned per a complaint at the edit warring noticeboard. If either of you reverts again at Nootropic without getting a prior consensus in your favor on the talk page that person may be blocked. This shouldn't discourage you from active participation on Talk. Thank you, EdJohnston ( talk) 22:41, 12 July 2018 (UTC)
My draft text did not assert that Nagajoshi synthesized amphetamine. Instead, he purifed and characterized ephedrine from Ephedra. He then devised a synthesis for *ephedrine.* (not amphetamine.) — Preceding unsigned comment added by Sbelknap ( talk • contribs) 19:01, 18 July 2018 (UTC)
Sunday, September 30, 11:00-4:00 PM
Pan Pacific Park, 7600 Beverly Blvd, Los Angeles, CA 90036
Hang out. Consume
crowd-sourced BBQ! Bask in the glory of late September in Los Angeles (and the glory
of our new user group,
Wikimedians of Los Angeles).
RSVP (and volunteer)
here.
We hope to see you there!
JSFarman (
talk) 02:50, 9 September 2018 (UTC)
Join our
Facebook group, or follow us on
Twitter!
Just a heads-up, sci-hub is blacklisted across the wikipedia realm. Please don't give links to it (actual *links* won't be possible, and <nowiki> wrappers could give the appearance that you are trying to circumvent that policy). The links don't always work anyway (as sci-hub keeps changing sites). But instead, {{ DOI}} can be used as a valid link. And if you like using sci-hub, the doi is apparently sufficient to find an article on it. I and others are gradually removing existing existing links to prevent others from having difficulty with it. DMacks ( talk) 12:28, 17 October 2018 (UTC)
Howdy! Based on some of the templates you have recently edited, I'm hoping you might be interested in helping me out with a project. I'm working on building a {{ Infobox}} based replacement for {{ Chembox}}. I have a working proof of concept at {{ Infobox chemical}}. Looking for some expert opinions and feedback. If you have any interest, please let me know. Feel free to disregard this message. :-) (P.S. Happy thanksgiving if you are in the USA!) -- Zackmann ( Talk to me/ What I been doing) 19:15, 22 November 2018 (UTC)
To your summary: no, it does not imply racemate. Read e.g. this. (By the way, I won't call you moron for re-enabling disputed image, it would be rude). Regards, — Mykhal ( talk) 16:30, 5 December 2018 (UTC)
"And the angel said unto them, Fear not: for, behold,
I bring you good tidings of great joy, which shall be to all people.
For unto you is born this day in the city of David a Saviour, which is Christ the Lord."
Luke 2:10-11 (King James Version)
Ozzie10aaaa ( talk) is wishing you a Merry Christmas.
This greeting (and season) promotes WikiLove.
-- Ozzie10aaaa ( talk) 14:09, 13 December 2018 (UTC)
Merry Christmas and a Prosperous 2019! | |
Hello Seppi333, may you be surrounded by peace, success and happiness on this
seasonal occasion. Spread the
WikiLove by wishing another user a
Merry Christmas and a
Happy New Year, whether it be someone you have had disagreements with in the past, a good friend, or just some random person. Sending you heartfelt and warm greetings for Christmas and New Year 2019. Spread the love by adding {{ subst:Seasonal Greetings}} to other user talk pages. |
Hello, Seppi333. I promised you I'd reply to your extensive post at Wikipedia talk:WikiProject Medicine/Archive 119. I'm afraid it's taken me a week and a half and the section has been archived. I'm replying on your talk page, but please feel free to move the content elsewhere if you prefer (or of course just delete it).
You are correct to say that I know little about addiction. Thank you for the detailed and helpful reply; it has been very useful to me in improving my understanding. I've read all the articles you linked to, and quite a few directly or indirectly linked off of them, and some of the sources for them and related sources. I think I now have a somewhat better understanding; not your knowledge or perspective, but some useful concepts, like the wanting/liking distinction (the terminology here is a bit confusing; "hedonia", for instance, seems to be used to refer to a)just the the liking and b)both the liking and the wanting together; the relationship between these and the dopamine and opoid systems is also not yet clear to me). The coverage of the difference between dependence and addiction is also much clearer in addiction than nicotine dependence. I've taken notes, and once I think I understand the concepts well enough, I'll try and clarify the bits that confused me when first reading them. I've been focussing on some of the studies around natural rewards, to start on more familiar ground. I hope you will continue to correct me if you see problems with my edits.
You are certainly better acquainted with your beliefs and knowledge than I, and I was not trying to tell you about either. My apologies for failing to make this clear. I didn't know of studies on multigenerational cognitive effects of nicotine; are you referring to this paper (with an impressively dense COI statement)? I was writing on COIs, and COIs in research papers, and you can probably guess the tie. I've written a fair bit in nicotine marketing, which sheds an interesting side light on pathways of addiction (I've also been arguing with editors who are Phillip Morris employees, which I fear has affected how I've been interacting with other editors).
When thinking of the marginal cognitive benefits of psychostimulants, I was rather going by adrenaline, which I knew to be conditional in its cognitive effects (which presumably have survival value). I'd never come across the idea of taking nicotine to enhance cognition before reading it in the nicotine article. I'll have to read some more on the subject. HLHJ ( talk) 15:34, 3 December 2018 (UTC)
Hi Seppi, I'm not sure I agree with your revert here. I was not familiar with the term myself, but looking it up, it has seen substantial use in the literature. Also levarterenol redirects to norepinephrine, so the term really ought to appear in the article somewhere. Looie496 ( talk) 13:51, 3 July 2018 (UTC)
Why did you remove my copyedit of the HMB introduction? Everything I removed from the intro is repeated word for word in the article body, and shorter introductions are what I’m accustomed to seeing on Wikipedia. What makes the HMB article different? Dogshu ( talk) 03:09, 29 August 2018 (UTC) https://en.m.wikipedia.org/?title=Beta-Hydroxy_beta-methylbutyric_acid&oldid=856827744
Hello Seppi - can i ask you to reconsider your recent change of deltaFosB to use of Greek letter - (symbol), it is unreadable to any reader without the knowledge of the symbol - and is unsearchable on the page. if i make a change - feel free to revert. best -- Iztwoz ( talk) 10:45, 14 March 2019 (UTC)
Hi Seppi - I'm so sorry to have missed the post you made at WT:MED/Archive_124. I wanted to just add a quick note here that I think something like what you're talking about could very well be published through WikiJMed. There are some editors at WikiJSci (especially User:Jacknunn ( link) who could advise on considerations and format, and help out in gathering suitable peer reviewers. Depending on exactly what description and analyses are being done, it could be a series of small publications, or a single publication that goes through multiple versions as new parts are added (versioning like a textbook, or extending with addenda). Let me know if you're still interested in the idea. T.Shafee(Evo&Evo) talk 07:05, 27 June 2019 (UTC)
|
This is an archive of past discussions. Do not edit the contents of this page. If you wish to start a new discussion or revive an old one, please do so on the current talk page. |
Archive 1 | Archive 2 |
Seppi333,
May I use your material ( /info/en/?search=Template:Psychostimulant_addiction) in a presentation to a college of pharmacy? If so how would you like for me to attribute credit to you? I'll be making alterations to focus the material on my presentation topic.
(I'm a wikipedia newb...)
Cicatrix768 Cicatrix768 ( talk) 16:05, 3 November 2016 (UTC)
@ Boghog: You gave me a lot of feedback when I was creating this diagram, so I was wondering what you thought about this. How do you feel about this proposed revision? Seppi333 ( Insert 2¢) 05:25, 6 November 2016 (UTC)
References for this section
|
---|
|
Has anyone proposed a multiple column TOC option? You know how damn much white space growing TOCs create; the horizontal layout can fix this dead space but is terrible to use. (I believe that you've been positioning the addiction glossary to compensate, in part.) What are your thoughts on multi-column TOCs? — βox73 (৳alk) 13:26, 25 January 2017 (UTC)
{{
TOC limit}}
or merge subsections within an article into their parent headings.
Seppi333 (
Insert 2¢) 21:49, 25 January 2017 (UTC){{
Addiction glossary}}
is based upon {{
Transcription factor glossary}}
and similar glossaries, so I'll need to change the header color in several templates when I implement it.{{
Addiction glossary}}
has a |class=
parameter for setting the table class; in the amphetamine article, this parameter is set to "wikitable mw-collapsible mw-collapsed". The default class parameter for the addiction glossary is "toccolours", which is not a wikitable class. When using the "toccolours" class parameter, the rows within a table are not partitioned by table cells like they are when using a wikitable class.{{
Addiction glossary}}
and {{
Transcription factor glossary}}
?
Seppi333 (
Insert 2¢) 19:24, 28 January 2017 (UTC)
Are you still blocked? According to Special:BlockList, you are not. Let me know. I am watching this page. - Ad Orientem ( talk) 04:07, 26 February 2017 (UTC)
Check your email. - Ad Orientem ( talk) 00:07, 27 February 2017 (UTC)
Hello:
I am an undergraduate student at LSE. Psychology is my optional course. Enriching a psychological entry on Wikipedia is one of our assessment. Reward system is the entry allocated to me. We have to write 750-1000 words in addition to the original piece. I am totally a new hand to Wikipedia. If I do something not very good, please feel free to give me your advice! Thank you! — Preceding unsigned comment added by XUY49 ( talk • contribs) 00:25, 14 March 2017 (UTC)
Two years! |
---|
-- Gerda Arendt ( talk) 07:12, 3 April 2017 (UTC)
Please check out my comment.-- Penbat ( talk) 10:19, 9 April 2017 (UTC)
You're a fine editor but I take issue with the abrasive tone of your edit summaries regardless of their validity. But this went further. I don't want interact with you. I can't, at least presently. — βox73 (৳alk) 01:57, 20 April 2017 (UTC)
Seppi, would you like me to post this GA nom,beta-Hydroxy beta-methylbutyric acid to do Wikipedia_talk:WikiProject_Medicine so you can get the ball rolling, let me know(I'm sure it'll pass easily)-- Ozzie10aaaa ( talk) 10:37, 20 April 2017 (UTC)
Please can you do a one or two paragraph subsection on Addiction here Reinforcement#Applications thanks. I've done a placeholder inspired by you last edit :-) Reinforcement#Addiction -- Penbat ( talk) 22:04, 17 May 2017 (UTC)
Reflist
|
---|
References
|
It is definately good enough for now. Thanks. Hopefuly you will get time to develop it further at some point.-- Penbat ( talk) 08:55, 18 May 2017 (UTC)
Hi. We're into the last five days of the Women in Red World Contest. There's a new bonus prize of $200 worth of books of your choice to win for creating the most new women biographies between 0:00 on the 26th and 23:59 on 30th November. If you've been contributing to the contest, thank you for your support, we've produced over 2000 articles. If you haven't contributed yet, we would appreciate you taking the time to add entries to our articles achievements list by the end of the month. Thank you, and if participating, good luck with the finale! — Preceding unsigned comment added by MediaWiki message delivery ( talk • contribs) 03:11, 26 November 2017 (UTC)
Thanks for the thanks Seppi -- Iztwoz ( talk) 23:18, 24 March 2017 (UTC)
Thanks for having a look at the article and making some changes, Seppi333. We're aiming to nominate for GA at some point in the medium term.
It's been quite hard given the extensive role of the human brain to balance accuracy, prose length, comprehensiveness and readability. If you haven't had a look through the whole article I'd be quite grateful if you could skim along to make sure there's nothing unusual about it, given you're one of the few editors around who may have an informed view about it. There's a couple of editors (including one now blocked from editing it) so we can't speak to all the edits, and I plan on editing to finish up the modern history and clinical significance sections tonight... but for an article like this, more eyes will be better
Hope that you're well, -- Tom (LT) ( talk) 21:01, 25 March 2017 (UTC)
The 2016 Cure Award | |
In 2016 you were one of the top ~200 medical editors across any language of Wikipedia. Thank you from Wiki Project Med Foundation for helping bring free, complete, accurate, up-to-date health information to the public. We really appreciate you and the vital work you do! Wiki Project Med Foundation is a user group whose mission is to improve our health content. Consider joining here, there are no associated costs. |
Thanks again :-) -- Doc James along with the rest of the team at Wiki Project Med Foundation 18:08, 3 May 2017 (UTC)
Your account has been granted the "templateeditor" user permission, allowing you to edit templates and modules that have been protected with template protection. It also allows you to bypass the title blacklist, giving you the ability to create and edit editnotices. Before you use this user right, please read Wikipedia:Template editor and make sure you understand its contents. In particular, you should read the section on wise template editing and the criteria for revocation.
You can use this user right to perform maintenance, answer edit requests, and make any other simple and generally uncontroversial edits to templates, modules, and edinotices. You can also use it to enact more complex or controversial edits, after those edits are first made to a test sandbox, and their technical reliability as well as their consensus among other informed editors has been established. If you are willing to process edit requests on templates and modules, keep in mind that you are taking responsibility to ensure the edits have consensus and are technically sound.
This user right gives you access to some of Wikipedia's most important templates and modules; it is critical that you edit them wisely and that you only make edits that are backed up by consensus. It is also very important that no one else be allowed to access your account, so you should consider taking a few moments to secure your password.
If you do not want this user right, you may ask any administrator to remove it for you at any time.
Happy template editing! Alex Shih Talk 12:10, 10 July 2017 (UTC)
On 12 July 2017, Did you know was updated with a fact from the article Pavlovian-instrumental transfer, which you recently created, substantially expanded, or brought to good article status. The fact was ... that a classically conditioned stimulus can affect operant behavior and motivation through Pavlovian-instrumental transfer? The nomination discussion and review may be seen at Template:Did you know nominations/Pavlovian-instrumental transfer. You are welcome to check how many page hits the article got while on the front page ( here's how, Pavlovian-instrumental transfer), and it may be added to the statistics page if the total is over 5,000. Finally, if you know of an interesting fact from another recently created article, then please feel free to suggest it on the Did you know talk page.
Alex Shih Talk 00:02, 12 July 2017 (UTC)
Thanks for your help! :3 2601:19A:4003:50:708B:26A:171F:F407 ( talk) 03:42, 14 July 2017 (UTC)
Hello. Your account has been granted the "pending changes reviewer" userright, allowing you to review other users' edits on pages protected by pending changes. The list of articles awaiting review is located at Special:PendingChanges, while the list of articles that have pending changes protection turned on is located at Special:StablePages.
Being granted reviewer rights neither grants you status nor changes how you can edit articles. If you do not want this user right, you may ask any administrator to remove it for you at any time.
See also:
Malinaccier ( talk) 16:26, 31 July 2017 (UTC)
I was wondering what you think about elaborating more about the effects of DA signalling on downstream targets such as the beta subunits of GABA, trafficking of GluA1/GluN2B, and mTOR signalling. I dont see much of that in the dopamine or dopamine receptor articles, and was wondering if you had any thoughts about where these additions would go if they were significant enough. Im considering adding a lot of it to the nucleus accumbens article, since quite a lot of this research bas focused in signalling in NAcc MSNs. Petergstrom ( talk) 22:00, 30 August 2017 (UTC)
{{
psychostimulant addiction}}
is that it involved 2 signaling pathways that converge at We stick with secondary source generally. I am not supportive of filling articles full of case reports. IMO that is clutter. Doc James ( talk · contribs · email) 17:23, 28 September 2017 (UTC)
Hey,
I think it's time that we try to follow through on the page rename from Adderall to Mixed Amphetamine Salts that was recently discussed on Talk:Amphetamine (specifically at Talk:Amphetamine/Archive 7#Mydayis). Box73 agreed when you asked him about his opinion on it and the only glimmer of opposition was from an IP editor that did not seem to be acquainted with the topic and did not further participate in the discussion after their initial comment.
I have created a draft article in my userspace with my proposed edits to Adderall in it that would sufficiently expand the scope of the article to include the other two MAS products and take the focus away from Adderall specifically and change it to the broader scope of mixed amphetamine salts. It's accessible at User:Garzfoth/Draft:Mixed Amphetamine Salts. While some additional work needs to be done to more clearly explain the differences between equivalent mixtures of amphetamine bases and actual mixtures of amphetamine salts, my recent re-read of FDA application # 208147Orig1s000 for Dyanvel made it clear to me that it is indeed completely appropriate to categorize the salts and the equivalent mixtures of bases under the same article/name, and I made enough changes to hopefully communicate the basics without being misleading (difficult to do in this case).
I am a bit uncertain about how exactly the process to proceed would work. It seems that I would need to follow the process in Wikipedia:Requested_moves#Requesting_controversial_and_potentially_controversial_moves, but I wanted to run this by you before starting anything so I could get your feedback on the proposed edits in my draft first, and I'm not certain about some of the particularities of moving this page (the problem is mainly that I don't know if it'd be better to make the edits prepared on User:Garzfoth/Draft:Mixed Amphetamine Salts when I request the move, or if I should wait until the move is approved even though the edits and the move should really go hand-in-hand — but I am also not sure if I need to reiterate all of my arguments in a move request, or if I can just briefly summarize them and link to the past two places where I went into more detail - I don't want to end up with a 35,000–45,000 char request that has to be mostly collapsed, which is approximately what it'd end up being if I actually rehashed all of my arguments within the request in full detail and included all those refs I dug up, as well as the new ones I now have...any advice on that?). Garzfoth ( talk) 08:04, 14 October 2017 (UTC)
Thank you for the excellent work at Template talk:Tryptophan metabolism by human microbiota - you've convinced me of the value of annotated diagrams! Slashme ( talk) 21:58, 2 November 2017 (UTC) |
| wydte = 580
parameter to | wydte = 600
.{{
Annotated image 4}}
specify the width and height of the thumbnail for the image; the "image-width" parameter specifies the width of the image (the image's height is automatically scaled based upon that value and its aspect ratio). The reason there's two width parameters is to allow you to crop or expand the area around the top/bottom/left/right sides of any image; using the "image-top", "image-left", "image-width", "width", and "height" parameters together lets you crop/expand images like that.
Seppi333 (
Insert 2¢) 22:28, 2 November 2017 (UTC)
Please be aware that your signature uses deprecated <font>
tags, which are causing
Obsolete HTML tags lint errors. You are encouraged to change
[[User:Seppi333|'''<font color="#32CD32">Seppi</font>''<font color="Black">333</font>''''']] ([[User Talk:Seppi333|Insert '''2¢''']])
→
Seppi333 (
Insert 2¢)to
[[User:Seppi333|'''<span style="color: #32CD32;">Seppi</span>''<span style="color: Black;">333</span>''''']] ([[User Talk:Seppi333|Insert '''2¢''']])
→
Seppi333 (
Insert 2¢)That's my 2¢.— Anomalocaris ( talk) 06:44, 9 November 2017 (UTC)
That's my 2¢– LOL. Anyway, I've made the changes you've indicated. Thanks for letting me know. Seppi333 ( Insert 2¢) 06:50, 9 November 2017 (UTC)
Hello, Seppi333.
I noticed you've done some constructive editing recently. |
{{
NPR invite}}
template needs to be substituted (i.e., use {{subst:NPR invite}}
instead of {{NPR invite}}
); otherwise, it doesn't add your signature.
Seppi333 (
Insert 2¢) 07:08, 21 November 2017 (UTC)
Hello Seppi333. Your account has been added to the "New page reviewers
" user group, allowing you to review new pages and mark them as
patrolled, tag them for maintenance issues, or in some cases, tag them for deletion. The list of articles awaiting review is located at the
New Pages Feed. New page reviewing is a vital function for policing the quality of the encylopedia, if you have not already done so, you must read the new tutorial at
New Pages Review, the linked guides and essays, and fully understand the various
deletion criteria. If you need more help or wish to discuss the process, please join or start a thread at
page reviewer talk.
The reviewer right does not change your status or how you can edit articles. If you no longer want this user right, you may ask any administrator to remove it for you at any time. In case of abuse or persistent inaccuracy of reviewing, the right can be revoked at any time by an administrator. TonyBallioni ( talk) 15:10, 21 November 2017 (UTC)
Hello Seppi333,
Please could you explain why my edit was wrong/bad and why you reverted it in this edit? Thank you! -- Treetear ( talk) 22:59, 25 November 2017 (UTC)
Hi there, I'm pleased to inform you that I've begun reviewing the article Beta-Hydroxy beta-methylbutyric acid you nominated for GA-status according to the criteria. This process may take up to 7 days. Feel free to contact me with any questions or comments you might have during this period. Message delivered by Legobot, on behalf of Tom (LT) -- Tom (LT) ( talk) 06:01, 28 November 2017 (UTC)
The Wikimedia Foundation Community health initiative (led by the Safety and Support and Anti-Harassment Tools team) is conducting a survey for en.wikipedia contributors on their experience and satisfaction level with the Administrator’s Noticeboard/Incidents. This survey will be integral to gathering information about how this noticeboard works - which problems it deals with well, and which problems it struggles with.
The survey should take 10-20 minutes to answer, and your individual responses will not be made public. The survey is delivered through Google Forms. The privacy policy for the survey describes how and when Wikimedia collects, uses, and shares the information we receive from survey participants and can be found here:
If you would like to take this survey, please sign up on this page, and a link for the survey will be mailed to you via Special:Emailuser.
Please be aware this survey will close Friday, Dec. 8 at 23:00 UTC.
Thank you on behalf of the Support & Safety and Anti-Harassment Tools Teams, Patrick Earley (WMF) talk 21:14, 6 December 2017 (UTC)
Hi there! In your revert of my edit of Transactivation you commented that "Wikilinks should not be placed inside a reference quote". Could you please substantiate that? DadaNeem ( talk) 22:49, 11 December 2017 (UTC)
Hi. You recently changed the LRT page by switching the numerator and denominator in the definition of LR. As I understand it (I am not an expert) it occurs both ways in the literature, so either way is OK, but now there are inconsistencies, I believe, with other parts of the article. e.g.: in the 'Simple hypotheses' section: 'In the form stated here, the likelihood ratio is small if the alternative model is better than the null model.', and in the 'Interpretation' section: 'The likelihood ratio test rejects the null hypothesis if the value of this statistic is too small.', and 'The numerator corresponds to the likelihood of an observed outcome under the null hypothesis. The denominator ...'. And maybe there are other inconsistencies. I don't know whether is would be better to revert to null model likelihood in numerator, or fix the statements inconsistent with your version. Perhaps you could do one or the other. Thanks. tom fisher-york ( talk) 18:24, 22 December 2017 (UTC)
Looks like I was confused about who did the latest revision. I'll put this on the article's talk page as I should have. — Preceding unsigned comment added by Tomfy ( talk • contribs) 18:33, 22 December 2017 (UTC)
Hi Seppi333, I just wanted to let you know that I have added the "autopatrolled" permission to your account, as you have created numerous, valid articles. This feature will have no effect on your editing, and is simply intended to reduce the workload on new page patrollers. For more information on the autopatrolled right, see Wikipedia:Autopatrolled. Feel free to leave me a message if you have any questions. Happy editing! TonyBallioni ( talk) 05:46, 23 December 2017 (UTC)
Merry Christmas and a Prosperous 2018! | |
Hello Seppi333, may you be surrounded by peace, success and happiness on this
seasonal occasion. Spread the
WikiLove by wishing another user a
Merry Christmas and a
Happy New Year, whether it be someone you have had disagreements with in the past, a good friend, or just some random person. Sending you a heartfelt and warm greetings for Christmas and New Year 2018. Spread the love by adding {{ subst:Seasonal Greetings}} to other user talk pages. |
A blessed feast to you and yours. - Ad Orientem ( talk) 15:22, 25 December 2017 (UTC)
The article Beta-Hydroxy beta-methylbutyric acid you nominated as a good article has passed ; see Talk:Beta-Hydroxy beta-methylbutyric acid for comments about the article. Well done! If the article has not already been on the main page as an "In the news" or "Did you know" item, you can nominate it to appear in Did you know. Message delivered by Legobot, on behalf of Tom (LT) -- Tom (LT) ( talk) 22:41, 25 December 2017 (UTC)
Hi Seppi333, here is the hatnote from Template:Main section. Credit to Mclay1 who originally wrote this. {{Hatnote|The main section for this topic is on the page [[{{{1}}}]], in the section [[{{{1}}}#{{{2}}}|{{{2}}}]].}}
Actually I am his father, and I don't know the details of where the insignia were worn. Feel free to adjust
ed
Ecragg ( talk) 10:39, 9 February 2018 (UTC)
Hey Seppi333, I just wanted to notify you as to an edit on the nucleus accumbens page I just made. From what was already written in the function section, it seemed as if the page was suggesting that increased excitability in NAcc MSNs is responsible for reward, so I changed the wording a bit, along with adding reviews of how reduced excitability is the predominant response in the NAcc. Petergstrom ( talk) 17:57, 10 February 2018 (UTC)
can you help User talk:Doc James#apparently not?(update... whenever you have time, just realized you've been out for 2 weeks)-- Ozzie10aaaa ( talk) 21:32, 3 March 2018 (UTC)
Three years! |
---|
-- Gerda Arendt ( talk) 10:27, 3 April 2018 (UTC)
Thank you for Beta-Hydroxy beta-methylbutyric acid, "a natural product in humans which is used as a medical food ingredient and dietary supplement; it has medical and athletic performance-enhancing applications for preventing/reversing muscle wasting and improving body composition respectively"! - I'd have difficulties to even remember the name, and appreciate highly what you did to make us understand. -- Gerda Arendt ( talk) 06:30, 28 May 2018 (UTC)
I have created new content about chromium dietary supplements. Because I have a declared COI, I placed it as New section in Chromium deficiency Talk. I am asking you and several other editors with an interest in nutrition/supplements to look at it and comment, perhaps making changes and/or stating that it is appropriate to move into the article, or not. A separate question is whether it belongs in Chromium deficiency, Chromium, or both. Thank you for the consideration. David notMD ( talk) 11:49, 16 April 2018 (UTC)
Hello,
There will be some changes to the way wikitext is parsed during the next few weeks. It will affect all namespaces. You can see a list of pages that may display incorrectly at Special:LintErrors. Since most of the easy problems have already been solved at the English Wikipedia, I am specifically contacting tech-savvy editors such as yourself with this one-time message, in the hope that you will be able to investigate the remaining high-priority pages during the next month.
There are approximately 10,000 articles (and many more non-article pages) with high-priority errors. The most important ones are the articles with misnested tags and table problems. Some of these involve templates, such as infoboxes, or the way the template is used in the article. In some cases, the "error" is a minor, unimportant difference in the visual appearance. In other cases, the results are undesirable. You can see a before-and-after comparison of any article by adding ?action=parsermigration-edit to the end of a link, like this: /info/en/?search=Arthur_Foss?action=parsermigration-edit (which shows a difference in how {{ infobox ship}} is parsed).
If you are interested in helping with this project, please see Wikipedia:Linter. There are also some basic instructions (and links to even more information) at https://lists.wikimedia.org/pipermail/wikitech-ambassadors/2018-April/001836.html You can also leave a note at WT:Linter if you have questions.
Thank you for all the good things you do for the English Wikipedia. Whatamidoing (WMF) ( talk) 21:18, 19 April 2018 (UTC)
Hello Seppi333. You've been warned per a complaint at the edit warring noticeboard. If either of you reverts again at Nootropic without getting a prior consensus in your favor on the talk page that person may be blocked. This shouldn't discourage you from active participation on Talk. Thank you, EdJohnston ( talk) 22:41, 12 July 2018 (UTC)
My draft text did not assert that Nagajoshi synthesized amphetamine. Instead, he purifed and characterized ephedrine from Ephedra. He then devised a synthesis for *ephedrine.* (not amphetamine.) — Preceding unsigned comment added by Sbelknap ( talk • contribs) 19:01, 18 July 2018 (UTC)
Sunday, September 30, 11:00-4:00 PM
Pan Pacific Park, 7600 Beverly Blvd, Los Angeles, CA 90036
Hang out. Consume
crowd-sourced BBQ! Bask in the glory of late September in Los Angeles (and the glory
of our new user group,
Wikimedians of Los Angeles).
RSVP (and volunteer)
here.
We hope to see you there!
JSFarman (
talk) 02:50, 9 September 2018 (UTC)
Join our
Facebook group, or follow us on
Twitter!
Just a heads-up, sci-hub is blacklisted across the wikipedia realm. Please don't give links to it (actual *links* won't be possible, and <nowiki> wrappers could give the appearance that you are trying to circumvent that policy). The links don't always work anyway (as sci-hub keeps changing sites). But instead, {{ DOI}} can be used as a valid link. And if you like using sci-hub, the doi is apparently sufficient to find an article on it. I and others are gradually removing existing existing links to prevent others from having difficulty with it. DMacks ( talk) 12:28, 17 October 2018 (UTC)
Howdy! Based on some of the templates you have recently edited, I'm hoping you might be interested in helping me out with a project. I'm working on building a {{ Infobox}} based replacement for {{ Chembox}}. I have a working proof of concept at {{ Infobox chemical}}. Looking for some expert opinions and feedback. If you have any interest, please let me know. Feel free to disregard this message. :-) (P.S. Happy thanksgiving if you are in the USA!) -- Zackmann ( Talk to me/ What I been doing) 19:15, 22 November 2018 (UTC)
To your summary: no, it does not imply racemate. Read e.g. this. (By the way, I won't call you moron for re-enabling disputed image, it would be rude). Regards, — Mykhal ( talk) 16:30, 5 December 2018 (UTC)
"And the angel said unto them, Fear not: for, behold,
I bring you good tidings of great joy, which shall be to all people.
For unto you is born this day in the city of David a Saviour, which is Christ the Lord."
Luke 2:10-11 (King James Version)
Ozzie10aaaa ( talk) is wishing you a Merry Christmas.
This greeting (and season) promotes WikiLove.
-- Ozzie10aaaa ( talk) 14:09, 13 December 2018 (UTC)
Merry Christmas and a Prosperous 2019! | |
Hello Seppi333, may you be surrounded by peace, success and happiness on this
seasonal occasion. Spread the
WikiLove by wishing another user a
Merry Christmas and a
Happy New Year, whether it be someone you have had disagreements with in the past, a good friend, or just some random person. Sending you heartfelt and warm greetings for Christmas and New Year 2019. Spread the love by adding {{ subst:Seasonal Greetings}} to other user talk pages. |
Hello, Seppi333. I promised you I'd reply to your extensive post at Wikipedia talk:WikiProject Medicine/Archive 119. I'm afraid it's taken me a week and a half and the section has been archived. I'm replying on your talk page, but please feel free to move the content elsewhere if you prefer (or of course just delete it).
You are correct to say that I know little about addiction. Thank you for the detailed and helpful reply; it has been very useful to me in improving my understanding. I've read all the articles you linked to, and quite a few directly or indirectly linked off of them, and some of the sources for them and related sources. I think I now have a somewhat better understanding; not your knowledge or perspective, but some useful concepts, like the wanting/liking distinction (the terminology here is a bit confusing; "hedonia", for instance, seems to be used to refer to a)just the the liking and b)both the liking and the wanting together; the relationship between these and the dopamine and opoid systems is also not yet clear to me). The coverage of the difference between dependence and addiction is also much clearer in addiction than nicotine dependence. I've taken notes, and once I think I understand the concepts well enough, I'll try and clarify the bits that confused me when first reading them. I've been focussing on some of the studies around natural rewards, to start on more familiar ground. I hope you will continue to correct me if you see problems with my edits.
You are certainly better acquainted with your beliefs and knowledge than I, and I was not trying to tell you about either. My apologies for failing to make this clear. I didn't know of studies on multigenerational cognitive effects of nicotine; are you referring to this paper (with an impressively dense COI statement)? I was writing on COIs, and COIs in research papers, and you can probably guess the tie. I've written a fair bit in nicotine marketing, which sheds an interesting side light on pathways of addiction (I've also been arguing with editors who are Phillip Morris employees, which I fear has affected how I've been interacting with other editors).
When thinking of the marginal cognitive benefits of psychostimulants, I was rather going by adrenaline, which I knew to be conditional in its cognitive effects (which presumably have survival value). I'd never come across the idea of taking nicotine to enhance cognition before reading it in the nicotine article. I'll have to read some more on the subject. HLHJ ( talk) 15:34, 3 December 2018 (UTC)
Hi Seppi, I'm not sure I agree with your revert here. I was not familiar with the term myself, but looking it up, it has seen substantial use in the literature. Also levarterenol redirects to norepinephrine, so the term really ought to appear in the article somewhere. Looie496 ( talk) 13:51, 3 July 2018 (UTC)
Why did you remove my copyedit of the HMB introduction? Everything I removed from the intro is repeated word for word in the article body, and shorter introductions are what I’m accustomed to seeing on Wikipedia. What makes the HMB article different? Dogshu ( talk) 03:09, 29 August 2018 (UTC) https://en.m.wikipedia.org/?title=Beta-Hydroxy_beta-methylbutyric_acid&oldid=856827744
Hello Seppi - can i ask you to reconsider your recent change of deltaFosB to use of Greek letter - (symbol), it is unreadable to any reader without the knowledge of the symbol - and is unsearchable on the page. if i make a change - feel free to revert. best -- Iztwoz ( talk) 10:45, 14 March 2019 (UTC)
Hi Seppi - I'm so sorry to have missed the post you made at WT:MED/Archive_124. I wanted to just add a quick note here that I think something like what you're talking about could very well be published through WikiJMed. There are some editors at WikiJSci (especially User:Jacknunn ( link) who could advise on considerations and format, and help out in gathering suitable peer reviewers. Depending on exactly what description and analyses are being done, it could be a series of small publications, or a single publication that goes through multiple versions as new parts are added (versioning like a textbook, or extending with addenda). Let me know if you're still interested in the idea. T.Shafee(Evo&Evo) talk 07:05, 27 June 2019 (UTC)
|